Abstract 808P
Background
Human papillomavirus (HPV) is the cause of the majority of cervical cancer cases and has been suggested to be released as cell-free DNA (ctHPV DNA) into the circulation. We here analyse if ctHPV DNA could be detected in plasma from patients with locally advanced cervical cancer (LACC) and if ctHPV DNA could be used as a prognostic biomarker and/or to detect relapses earlier than by traditional methods.
Methods
74 patients with LACC were included, 66/74 had biopsies positive for one of 13 high-risk HPV-types using a bead-based assay. Droplet digital PCR (ddPCR) assays were developed for the HPV-types found. 418 longitudinal plasma samples from these 66 patients were then analysed using ddPCR assays for the corresponding HPV-type found in the biopsies. Results were correlated to tumor- and clinical characteristics.
Results
92.4% of pre-treatment plasmas were positive for ctHPV DNA. ctHPV DNA levels were correlated to tumor stage. Persistent ctHPV DNA in end-of-treatment or early follow-up (1-4 months after finished treatment) plasma were correlated with worse progression-free survival (log rank test, p < 0.001) compared to if ctHPV DNA was not found. The positive predictive value (PPV) of ctHPV-status at early follow-up for predicting disease progression was 87.5% and the negative predictive value (NPV) was 89.3%. ctHPV DNA was found in plasma before relapse was diagnosed on radiology (median 315 days, mean 280 days) in all patients (n=10) who experienced relapsed after complete clinical response to treatment.
Conclusions
ctHPV DNA in follow-up plasma is a promising prognostic biomarker in patients with locally advanced cervical cancer, useful for analysis of response to therapy and for early detection of relapses. Drs. E. Tham and K. Hellman have equally contributed to the study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Karolinska Institutet, Magnus Bergvalls Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11